Rchr
J-GLOBAL ID：201301009478579550
Update date: Apr. 21, 2024
Oda Chigusa
オダ チグサ | Oda Chigusa
Affiliation and department：
Job title：
Associate Professor
Research theme for competitive and other funds (3)：
- 2023 - 2026 免疫受容体制御による新たな急性脊髄損傷治療体系の確立
- 2014 - 2017 Novel therapy for sepsis targeting to IgM receptor
- 2011 - 2013 Development of MAIR-I (CD300a) as a molecular target of sepsis treatment
Papers (56)：
-
H, Koizumi, Nakahashi-Oda C, Lyu W, Y, Yamashita-Kanemaru, K, Tabuchi, K., Shibuya, Shibuya, Akira. Development of monoclonal antibodies specific to either CD300AR111 or CD300AQ111 or both. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2023
-
小泉仁志, 小田, ちぐさ, 渋谷彰. CD300a阻害による脳梗塞後の神経障害の軽減. Journal of Clinical and Experimental Medicine. 2023
-
Miyashita, Daisuke, Inoue, Ryota, Tsuno, Takahiro, Okuyama, Tomoko, Kyohara, Mayu, Nakahashi-Oda, Chigusa, Nishiyama, Kuniyuki, Nishiyama, Kuniyuki, Inada, Yutaro, Togashi, Yu, et al. Protective effects of S100A8 on sepsis mortality: Links to sepsis risk in obesity and diabetes. iScience. 2022. 25. 12
-
Nishiyama, Nanako, Nakahashi-Oda, Chigusa, Shibuya, Akira. Interferon-beta promotes the survival and function of induced regulatory T cells. CYTOKINE. 2022. 158
-
Yuta Nakazawa, Nanako Nishiyama, Hitoshi Koizumi, Kazumasa Kanemaru, Chigusa Nakahashi-Oda, Akira Shibuya. Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. eLife. 2021. 10
ｍore...
MISC (3)：
-
小田 ちぐさ, 中橋, 田原 聡子, 安居 輝人, 菊谷 仁, 本多 伸一郎, 渋谷 和子, 長田 重一, 渋谷 彰. 炎症/病態 アポトーシス細胞と肥満細胞上のCD300aによる炎症応答の調節(Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor). 日本免疫学会総会・学術集会記録. 2011. 40. 232-232
-
Activating immune receptor MAIR-2 associates with DAP12 and FcRγ chain on peritoneal macrophages. Clinical immunology & allergology. 2010. 54. 2. 142-148
-
Activating immune receptor MAIR-2 associates with DAP12 and FcRγ chain on peritoneal macrophages. Clinical immunology & allergology. 2009. 52. 1. 26-33
Patents (13)：
-
ACTIVITY MODULATOR, MEDICINAL AGENT COMPRISING SAME, USE OF CD300A GENE-DEFICIENT MOUSE, AND ANTI-CD300A ANTIBODY
-
Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
-
アレルギー疾患に関する、CD300a発現細胞の活性調節剤を含有する医薬品、ならびにCD300a遺伝子欠損マウスおよびCD300a発現細胞の活性調節剤の使用
-
活性調節剤
-
活性調節剤、これを含有する医薬品、および抗CD300a抗体
ｍore...
Lectures and oral presentations (93)：
-
CD300a immunoreceptor exacerbates heart injury and adverse remodeling after myocardial infarction and reperfusion in mice
(第88回日本循環器学会学術集会)
-
CD300a immunoreceptor exacerbates acute kidney injury and fibrosis after renal ischemia and reperfusion in mice
(第52回日本免疫学会学術集会)
-
CD300a immunoreceptor exacerbates heart injury and adverse remodeling after myocardial infarction and reperfusion in mice
(第52回日本免疫学会学術集会)
-
The role of an immune-inhibitory receptor CD300a in kidney injury.
(JSICR/MMCB 2023 Joint meeting)
-
CD300a exacerbates heart injury and adverse remodeling after myocardial infarction.
(International Symposium on Immune Regulation)
ｍore...
Professional career (1)：
Return to Previous Page
